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Background: Acute administration of mitochondrial adenosine triphosphate–depen-
dent potassium channel openers preconditions the heart, but whether their long-term
administration induces a permanent state of protection is unknown. These studies
investigate the effect of long-term treatment with the mitochondrial adenosine
triphosphate–dependent potassium channel opener nicorandil on the response of the
human myocardium to ischemia and preconditioning.
Methods: Right atrial tissue obtained from patients regularly treated with or without
nicorandil (mean of 20 mg/d for 18.6 2.5 months) and undergoing cardiac surgery
was sliced and equilibrated for 30 minutes and then subjected to 90 minutes of
simulated ischemia, followed by 120 minutes of reoxygenation. In study 1 the
following groups were studied to investigate the effect of nicorandil on the suscep-
tibility of the myocardium to ischemia and on the protective effect of ischemic and
pharmacologic preconditioning: (1) aerobic control; (2) simulated ischemia and
reoxygenation alone; (3) ischemic preconditioning with 5 minutes of simulated
ischemia and 5 minutes of reoxygenation; and (4) phenylephrine (0.1 mol/L) for
5 minutes and 5 minutes’ washout before simulated ischemia and reoxygenation. In
study 2 the following groups were studied to investigate the effect of nicorandil on
the responsiveness of mitochondrial adenosine triphosphate–dependent potassium
channels: (1) aerobic control; (2) simulated ischemia and reoxygenation; (3) isch-
emic preconditioning; (4) diazoxide (100 mol/L) for 10 minutes before simulated
ischemia and reoxygenation, and (5) 5-hydroxydecanoate (1 mmol/L) for 10 min-
utes before simulated ischemia and reoxygenation. In study 3 the following groups
were included to investigate the effect of the long-term administration of nicorandil
on the kinase pathway involved in preconditioning: (1) aerobic control; (2) simu-
lated ischemia and reoxygenation alone; (3) ischemic preconditioning; (4) phorbol
12-myristate 13-acetate (1 mol/L), a protein kinase C activator, for 10 minutes
before simulated ischemia and reoxygenation; and (5) anisomycin (1 nmol/L), a p38
mitogen-activated protein kinase activator, for 10 minutes before simulated isch-
emia and reoxygenation. At the end of each protocol, the leakage of creatine kinase
(in units per gram wet weight) and the reduction of 3-[4,5 dimethylthiazol-2-yl]-2,5
diphenyltetrazolium bromide into insoluble formazan dye (in millimoles per gram
wet weight) were measured.
Results: In study 1 the leakage of creatine kinase and the reduction of 3-[4,5
dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide induced by simulated isch-
emia and reoxygenation were similar in the groups with or without nicorandil
(creatine kinase, 3.4  0.1 and 3.5  0.2, respectively; 3-[4,5 dimethylthiazol-2-
yl]-2,5 diphenyltetrazolium bromide, 74.6  3.9 and 67.9  7.3, respectively; P 
.2 in each instance). Ischemic preconditioning and pharmacologic preconditioning
protected the myocardium from patients without nicorandil (creatine kinase, 2.3 
0.1 and 2.4  0.1, respectively; 3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetrazo-
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lium bromide, 131.4  4.9 and 128.4  5.6, respectively; P  0.001 vs simulated
ischemia and reoxygenation alone in each instance) but not the myocardium from
patients receiving nicorandil (creatine kinase, 3.3 0.1 and 3.3 0.2, respectively;
3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide, 89.7  6.5 and
86.4  5.2, respectively; P  .2 vs simulated ischemia and reoxygenation alone in
each instance). In study 2 the administration of diazoxide had identical protection to
that of ischemic preconditioning in the myocardium of patients not receiving
nicorandil (creatine kinase, 2.1  0.2 and 2.3  0.1, respectively; 3-[4,5 dimeth-
ylthiazol-2-yl]-2,5 diphenyltetrazolium bromide, 141.4  7.4 and 131.4  4.9,
respectively; P  0.001 vs simulated ischemia and reoxygenation alone in each
instance) but failed to precondition the myocardium from patients treated with
nicorandil (creatine kinase, 3.3  0.2 and 3.4  0.1, respectively; 3-[4,5 dimeth-
ylthiazol-2-yl]-2,5 diphenyltetrazolium bromide, 90.1  7.2 and 86.4  5.2, re-
spectively; P  0.2 vs simulated ischemia and reoxygenation alone in each in-
stance). In study 3 phorbol 12-myristate 13-acetate or anisomycin given for 10
minutes before simulated ischemia and reoxygenation afforded similar protection to
that of ischemic preconditioning in the myocardium from patients with (creatine
kinase, 1.5  0.3 and 1.4  0.1, respectively; 3-[4,5 dimethylthiazol-2-yl]-2,5
diphenyltetrazolium bromide, 147.0  4.9 and 160.0  16.1, respectively; P 
0.001 vs simulated ischemia and reoxygenation alone in each instance) and without
nicorandil (creatine kinase, 1.7  0.4 and 1.4  0.2, respectively; 3-[4,5 dimeth-
ylthiazol-2-yl]-2,5 diphenyltetrazolium bromide, 160.3  13.6 and 158.3  11.8,
respectively; P  .001 vs simulated ischemia and reoxygenation alone in each
instance).
Conclusion: The myocardium of patients chronically treated with nicorandil cannot
be preconditioned either by ischemia or pharmacologically, and this is because of
unresponsive mitochondrial adenosine triphosphate–dependent potassium channels.
However, protection can be obtained by protein kinase C and p38 mitogen-activated
protein kinase activation, which are downstream of mitochondrial adenosine
triphosphate–dependent potassium channels in the signaling transduction pathway
of preconditioning.
Nicorandil was first introduced in clinicalpractice in 1984 as the first in a new classof antianginal drugs. Since then, it hasbecome widely used for the control ofangina as part of combination therapy,and more recently, it is being increasingly
used as the first-line and sole treatment in both stable1,2 and
unstable angina.3 Nicorandil is a nicotinamide nitrate ester
that has been shown to have an antianginal effect compa-
rable with that of -blockers and calcium antagonists. It has
a bimodal mechanism of action combining 2 vasodilator
mechanisms; it increases potassium conductance in the cell
membrane, resulting in potassium outflow from the cell and
causing membrane hyperpolarization4; and it also increases
cellular levels of cyclic guanosine monophosphate,5 with
both actions causing vasorelaxation. The nitrate-like action
of nicorandil dilates epicardial coronary arteries,6 which
results in an increase in the blood supply to the ischemic
region of the myocardium. In addition, nicorandil has been
shown to open adenosine triphosphate–dependent potas-
sium (KATP) channels in ischemic cardiomyocytes,7 and
there is strong evidence that the mitochondrial, rather than
the sarcolemmal, KATP channels are involved in the protec-
tion of ischemic preconditioning,8-11 probably by decreasing
the mitochondrial membrane potential.12,13 Yellon’s labora-
tory has reported that nicorandil can mimic the protection of
ischemic preconditioning,14 which has led to the suggestion
that patients receiving nicorandil for the control of angina
might be permanently protected.15
The aims of this study were to investigate the effects of
long-term administration of nicorandil on the tolerance of
the human myocardium to ischemia and on the protection of
ischemic and pharmacologic preconditioning and on its
signal transduction mechanism.
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Patient Selection and Experimental Preparation
Experiments were performed on muscle obtained from the right
atrial appendage of patients undergoing elective coronary artery
surgery in a cell necrosis model characterized in our laboratory and
described previously.16 Patients were excluded if they had large
atriums, atrial arrhythmias, poor left ventricular function (ejection
fraction 30%), diabetes, and right ventricular failure or were
receiving oral hypoglycemic agents, opioid analgesia, or cat-
echolamines. Patients taking nicorandil had their last dose on the
morning of the operation 2.5  0.4 hours before harvesting of the
atrial appendage. These patients were taking nicorandil for a mean
of 18.6  2.5 months at a mean dosage of 20 mg/d. Local ethical
committee approval was obtained for the harvesting technique.
The specimens were collected in oxygenated N-2-hydroxyeth-
ylpiperazine-N-2-ethanesulfonic acid buffered solution at 4°C to
5°C and immediately sectioned and prepared for study. The ap-
pendage was mounted onto a ground glass plate with the epicardial
surface face down and then sliced freehand (to prevent crushing)
with surgical skin graft blades (Shwann-Morton) to a thickness of
between 300 and 500 m. The muscles (weight, 30-50 mg) were
then transferred to conical flasks (25-mL Erlenmeyer flasks, Schott
Glaswerk) containing 10 mL of oxygenated buffered solution, and
the flasks were placed in a shaking water bath maintained at 37°C.
The oxygenation of the incubation medium was maintained by a
continuous flow of 95% O2/5% CO2 gas mixture to obtain a PO2 of
between 25 and 30 kPa and a PCO2 of between 6 and 6.5 kPa. The
PO2, PCO2, and pH in the incubation medium were monitored by
means of intermittent analyses of the solution with an automated
blood gas analyzer (model 855 Blood Gas System, Chiron Diag-
nostics), and the pH was kept at between 7.36 and 7.45. For the
induction of simulated ischemia, the medium was bubbled with
95% N2/5% CO2 (pH 6.80-7.00), and D-glucose was replaced with
2-deoxy glucose.
Assessment of Tissue Injury and Viability
Tissue injury was determined by measuring the leakage of creatine
kinase (CK) into the incubation medium during the 120-minute
reoxygenation period. This was assayed by using a kinetic UV
method on the basis of the formation of NAD (Sigma Catalogue
No. 1340-K), and the results were expressed as units per gram wet
weight.
Tissue viability was assessed by the reduction of 3-[4,5 dim-
ethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) to a
blue formazan product at the end of the experimental time. The
absorbance of the blue formazan formed was measured on a plate
reader (Benchmark, Bio-Rad Laboratories) at 550 nm, and the
results were expressed as millimoles per gram wet weight. In this
preparation the atrial tissue was not paced, and the force developed
was not measured.
Solutions and Drugs
The incubation medium was prepared daily with deionized dis-
tilled water and contained the following: NaCl2, 118 mmol/L; KCl,
4.8 mmol/L; NaHCO3, 27.2 mmol/L; MgCl2, 1.2 mmol/L;
KH2PO4, 1.0 mmol/L; CaCl2, 1.25 mmol/L; D-glucose, 10
mmol/L; and N-2-hydroxyethylpiperazine-N-2-ethanesulfonic
acid, 20 mmol/L. During simulated ischemia, D-glucose was sub-
stituted with 2-deoxy glucose (10 mmol/L) to maintain a constant
osmolarity. Phenylephrine, prazosin, 5-hydroxydecanoate, and
anisomycin were dissolved in deionized distilled water, whereas
diazoxide and phorbol 12-myristate 13-acetate (PMA) were dis-
solved in dimethyl sulfoxide. Anisomycin is an antibiotic that
inhibits protein synthesis and has been demonstrated to activate
p38 mitogen-activated protein kinase (MAPK), whereas PMA is a
phorbol ester that is widely used to activate protein kinase C
(PKC). All the drug doses were chosen after extensive preliminary
dose-response experiments. All reagents were obtained from
Sigma.
Experimental Protocols
All atrial muscles were allowed to equilibrate under aerobic con-
ditions for 30 minutes before 90 minutes of simulated ischemia
and 120 minutes of reoxygenation. There were 6 specimens in each
group from 6 different patients, with a total of 9 to 13 patients
being enrolled in each study.
Study 1: To investigate the effect of long-term admin-
istration of nicorandil on myocardial tolerance to isch-
emia and on protection of ischemic and pharmacologic
preconditioning with phenylephrine. Atrial muscles ob-
tained from appendages of patients treated or not treated
with nicorandil were randomly assigned to one of the fol-
lowing groups: (1) aerobic control; (3) simulated ischemia
and reoxygenation alone; (3) ischemic preconditioning with
5 minutes of simulated ischemia and 5 minutes of reoxy-
genation; and (4) phenylephrine (0.1 mol/L) for 5 minutes
and 5 minutes’ washout before simulated ischemia and
reoxygenation.
Study 2: To investigate the effect of long-term admin-
istration of nicorandil on responsiveness of mitochondrial
KATP channels during preconditioning. Atrial slices ob-
tained from appendages of patients treated or not treated
with nicorandil were randomly assigned to one of the
following groups: (1) aerobic control; (2) simulated isch-
emia and reoxygenation alone; (3) ischemic precondi-
tioning with 5 minutes of simulated ischemia and 5
minutes of reoxygenation; (4) diazoxide (100 mol/L), a
mitochondrial KATP channel opener, for 10 minutes be-
fore simulated ischemia and reoxygenation; and (5) 5-hy-
droxydecanoate (1 mmol/L), a mitochondrial KATP chan-
nel blocker, for 10 minutes before simulated ischemia
and reoxygenation.
Study 3: To investigate the effect of long-term admin-
istration of nicorandil on the kinase pathway involved in
preconditioning. Atrial slices obtained from appendages
of patients treated or not treated with nicorandil were
randomly assigned to one of the following groups: (1)
aerobic control; (2) simulated ischemia and reoxygen-
ation alone; (3) ischemic preconditioning with 5 minutes
of simulated ischemia and 5 minutes of reoxygenation;
(4) PMA (1 mol/L), a PKC activator, for 10 minutes
before simulated ischemia and reoxygenation; and (5)
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anisomycin (1 nmol/L), a p38MAPK activator, for 10
minutes before simulated ischemia and reoxygenation.
Statistical Analysis
All data are presented as means SEM. Mean values were compared
by means of analysis of variance with application of the post hoc
Tukey test.
Results
Effect of Long-Term Administration of Nicorandil on
Myocardial Tolerance to Ischemia and on Protection
of Ischemic and Pharmacologic Preconditioning with
Phenylephrine (Study 1)
As shown in Figure 1, the increased CK leakage and de-
creased MTT reduction induced by ischemia and reoxygen-
ation were similar in the muscles from patients with and
without long-term nicorandil treatment. Figure 1 also shows
that ischemic and pharmacologic preconditioning with
phenylephrine resulted in identical protection in the nic-
orandil-free group but failed to protect the myocardium in
the nicorandil-treated group.
Effect of Long-Term Administration of Nicorandil on
Responsiveness of Mitochondrial KATP Channels
During Preconditioning (Study 2)
As expected, Figure 2 shows that the selective opening of
mitochondrial KATP channels with diazoxide resulted in
protection (ie, reduced CK leakage and increased MTT
reduction) similar to that provided by ischemic precondi-
tioning, with no detrimental effect beyond that of ischemia
and reoxygenation alone when the channels were blocked
with 5-hydroxydecanoate. In contrast with these results,
diazoxide did not protect the myocardium in the nicorandil-
treated group.
Effect of Long-Term Administration of Nicorandil on
the Kinase Pathway Involved in Preconditioning
(Study 3)
The results shown in Figure 3 demonstrate that activation of
PKC and p38MAPK resulted in similar protection as that
provided by ischemic preconditioning, as shown on the
basis of the CK leakage and MTT reduction values in both
the nicorandil-free and nicorandil-treated groups.
Discussion
The present studies have demonstrated that the long-term
administration of nicorandil, a mitochondrial KATP channel
opener14 and nitric oxide donor,17 abolishes the ability of
the human myocardium to be protected by ischemic and
pharmacologic preconditioning without exacerbating the
susceptibility to ischemic injury. In addition, they have
shown that the likely cause of the failure to precondition the
myocardium of patients receiving nicorandil is the unre-
sponsiveness of the mitochondrial KATP channels because
protection cannot be obtained with diazoxide, a specific
mitochondrial KATP channel opener, but can be elicited by
activation of PKC and p38MAPK, which are downstream of
mitochondrial KATP channels in the signaling transduction
cascade of preconditioning.18 These results have important
clinical implications and shed light onto the mechanism of
protection by preconditioning that are discussed below.
Opening of the mitochondrial KATP channels has been
demonstrated to be an obligatory step in the signal trans-
duction mechanism of preconditioning.8,9,11 Thus nicorandil
and other mitochondrial KATP channel openers have been
shown to mimic the cardioprotection of ischemic precondi-
tioning when given acutely (ie, immediately before the
ischemic insult) in both animal7,11,15 and human8,9 studies.
As a result, and as suggested by Carr and Yellon,15 one
might be tempted to hypothesize that the long-term admin-
istration of mitochonrial KATP channel openers induces a
permanent state of protection against ischemic injury. How-
ever, the present studies are the first to report that when
mitochonrial KATP channel openers are given on a long-
term basis, as occurs clinically, these channels become
unresponsive, with loss of the cardioprotection of precon-
ditioning.
Our findings contrast with those reported by Carr and
Yellon15 showing that the long-term administration of nic-
orandil is actually protective. Their and our studies used
human atrial myocardium, and the only difference between
the 2 studies is that they assessed recovery of contractile
function in their study as opposed to tissue viability in ours,
which might offer an explanation as to the differing results.
Further fuel is added to the controversy when the same
authors observed that the protection of the myocardium of
patients receiving long-term nicorandil is in fact abolished
by the application of ischemic preconditioning. These re-
sults require clarification because it is difficult to understand
how 2 protective interventions using identical signal trans-
duction mechanisms can annul each other.
The mechanism by which the long-term administration
of nicorandil renders the mitochonrial KATP channels unre-
sponsive to preconditioning with ischemia and with diazox-
ide is not completely elucidated by the present studies, but
they have shown that the activation of kinases that we have
previously shown to be downstream of mitochonrial KATP
channels18 is unaffected because their activation can still
elicit protection. It has been suggested that the generation of
free radical species is the link between mitochonrial KATP
channels and the activation of PKC.11 If this is the case, then
it might be speculated that a permanent opening state of
mitochonrial KATP channels results in a reduction in the
formation of free radicals, a thesis that gains support from
the demonstration that nicorandil possesses antioxidant
properties.19
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The present studies raise fundamental questions on the
clinical utility and safety of nicorandil and other mitochon-
rial KATP channel openers for the control of angina symp-
toms. The permanent opening of the mitochonrial KATP
channels deprive the heart of the intrinsic protective mech-
anism of preconditioning that might be a risk factor in the
presence of ischemic heart disease. Therefore if the bene-
ficial action of nicorandil is solely due to its nitrate effect,
then the use of this compound might not be fully justified.
However, if, as discussed earlier, the maintenance of mito-
chonrial KATP channels in an open state might reduce the
generation of free radicals and oxidative stress, then these
beneficial effects of nicorandil might counterbalance the
loss of preconditioning. Indeed, oxidative stress has been
Figure 1. CK leakage into the media: A, during the 120-minute reoxygenation period and MTT reduction by the
slices; B, at the end of the reoxygenation period in human atrial myocardium subjected to various protocols (see
text for details) to investigate the effect of the long-term administration of nicorandil on the myocardial tolerance
to ischemia and on the protection of ischemic and pharmacological preconditioning with phenylephrine (study 1).
Data are expressed as means  SEM of 6 experiments. *P < .001 versus simulated ischemia and reoxygenation
alone.
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suggested as an important mechanism of many disease
states, including the inflammatory response in diabetes,20
atherosclerosis,21 cardiac hypertrophy,22 and heart failure.23
It is clear that further experimental and clinical studies are
required to fully elucidate the mechanism and the clinical
repercussions of nicorandil and similar agents on ischemic
heart disease and ischemic syndromes.
It is necessary to mention that our studies were per-
formed in an in vitro preparation that was not electrically
stimulated (ie, nonbeating), and it was not possible to obtain
functional data. Therefore any extrapolation to the clinical
setting should be made with caution. Another potential
limitation of our studies was the use of atrial, as opposed to
ventricular, myocardial tissue, and again, any extrapolation
Figure 2. CK leakage into the media: A, during the 120-minute reoxygenation period and MTT reduction by the
slices; B, at the end of the reoxygenation period in human atrial myocardium subjected to various protocols (see
text for details) to investigate the effect of the long-term administration of nicorandil on the responsiveness of
mitochondrial KATP channels during preconditioning (study 2). Data are expressed as means  SEM of 6
experiments. *P < .001 versus simulated ischemia and reoxygenation alone. 5-HD, 5-Hydroxydecanoate.
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of the conclusions from these studies to the ventricular
myocardium should also be made with caution.
Although these studies have demonstrated the unrespon-
siveness of the mitochonrial KATP channels as the cause of
failure to precondition the myocardium of nicorandil-treated
patients, they show that protection can still be obtained by
direct activation of PKC or p38MAPK, which are down-
stream of mitochonrial KATP channels in the signal trans-
duction pathway of ischemic preconditioning. Therefore
protection can be elicited by bypassing the steps of the
transduction cascade that might be affected by disease
states, such as diabetes or heart failure,24 or by medication,
such as sulphonylureas,24 and antianginal treatment, such as
nicorandil, as shown from the current studies. Undoubtedly
Figure 3. CK leakage into the media: A, during the 120-minute reoxygenation period and MTT reduction by the
slices; B, at the end of the reoxygenation period in human atrial myocardium subjected to various protocols (see
text for details) to investigate the effect of the long-term administration of nicorandil on the kinase pathway
involved in preconditioning (study 3). Data are expressed as means  SEM of 6 experiments. *P < .001 versus
simulated ischemia and reoxygenation alone.
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greater understanding of the various elements participating
in the signal transduction pathway and identification of
agents with selective activity on factors to avoid unwanted
side effects will be required before its use might be consid-
ered in the clinical setting.
References
1. Krumenacker M, Roland EO. Clinical profile of nicorandil: an over-
view of its haemodynamic properties and therapeutic efficacy. J Car-
diovasc Pharmacol. 1992;20:S93-102.
2. Frampton J, Buckley M, Fitton A. Nicorandil: a review of its phar-
macology and therapeutic efficacy in angina pectoris. Drugs. 1992;
44:625-55.
3. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the
KATP channel in unstable angina. Eur Heart J. 1999;20:51-7.
4. Cook NS. The pharmacology of potassium channels and their thera-
peutic potential. Trends Pharmacol Sci. 1988;9:21-8.
5. Flaherty JT. Nitrate tolerance: a review of the evidence. Drugs.
1989;37:523-50.
6. Suryapranata H, MacLeod D. Nicorandil and cardiovascular perfor-
mance in patients with coronary artery disease. J Cardiovasc Phar-
macol. 1992;20:S45-51.
7. Hiraoka M, Fan Z. Activation of ATP-sensitive outward potassium
current by nicorandil (2-nicotinamidoethyl-nitrate) in isolated ventric-
ular myocytes. J Pharmacol Exp Ther. 1989;250:278-85.
8. Speechly-Dick M, Grover G, Yellon DM. Does ischaemic precondi-
tioning in the human involve protein kinase C and the ATP-dependent
K channel? Circ Res. 1995;77:1030-5.
9. Ghosh S, Standen N, Galin˜anes. Evidence for mitochondrial channels
as effectors of human myocardial preconditioning. Cardiovasc Res.
2000;45:934-40.
10. Ghosh S, Standen N, Galin˜anes M. Preconditioning the human myo-
cardium by simulated ischemia: studies on the early and delayed
protection. Cardiovasc Res. 2000;45:339-50.
11. Pain T, Yang X, Critz SD, et al. Opening of mitochondrial KATP
channels triggers the preconditioned state by generating free radicals.
Circ Res. 2000;87:460-6.
12. Holmuhamedov EL, Jovanovic S, Dzeja PP, Jovanovic A, Terzic A.
Mitochondrial ATP-sensitive K channels modulate cardiac mito-
chondrial function. Am J Physiol Heart Circ Physiol. 1998;275:
H1567-76.
13. Liu Y, Sato T, Seharaseyon J, Szewczyk A, O’Rourke B, Marban E.
Mitochondrial ATP-dependent potassium channels. Viable candidate
effectors of ischemic preconditioning. Ann N Y Acad Sci. 1999;874:
27-37.
14. Imagawa J, Baxter GF, Yellon DM. Myocardial protection afforded by
nicorandil and ischaemic preconditioning in a rabbit infarct model in
vivo. J Cardiovasc Pharmacol. 1998;31:74-9.
15. Carr CS, Yellon DM. Ischaemic preconditioning may abolish the
protection afforded by ATP-sensitive potassium channel openers in
isolated human atrial muscle. Basic Res Cardiol. 1997;92:25-260.
16. Zhang JG, Ghosh S, Ockelford C, Galin˜anes M. Characterization of an
in vitro model for the study of the short and prolonged effects of
myocardial ischaemia and reperfusion in man. Clin Sci. 2000;99:339-
50.
17. Nishikawa Y, Kanki H, Ogawa S. Differential effects of N-acetylcys-
teine on nitroglycerin- and nicorandil-induced vasodilatation in human
coronary circulation. J Cardiovasc Pharmacol. 1998;32:21-8.
18. Loubani M, Galin˜anes M. MitoKATP channels are upstream of PKC
and p38MAPK activation in the preconditioning of the human myo-
cardium by alpha 1 adrenoceptors [abstract]. Eur Heart J. 2001;22:
384.
19. Naito A, Aniya Y, Sakanashi M. Antioxidative action of nitrovasodi-
lator nicorandil: inhibition of oxidative activation of liver microsomal
glutathione S-transferase and lipid peroxidation. Jpn J Pharmacol.
1994;65:209-13.
20. Matata BM, Galin˜anes M. Cardiopulmonary bypass exacerbates oxi-
dative stress but does not increase proinflammatory cytokine release in
patients with diabetes compared with patients without diabetes: reg-
ulatory effects of exogenous nitric oxide. J Thorac Cardiovasc Surg.
2000;120:1-11.
21. Langlois M, Duprez D, Delanghe J, De Buyzere M, Clement DL.
Serum vitamin C concentration is low in peripheral arterial disease
and is associated with inflammation and severity of atherosclerosis.
Circulation. 2001;103:1863-8.
22. Nagueh SF, Stetson SJ, Lakkis NM, et al. Decreased expression of
tumor necrosis factor-alpha and regression of hypertrophy after non-
surgical septal reduction therapy for patients with hypertrophic ob-
structive cardiomyopathy. Circulation. 2001;103:1844-50.
23. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxyni-
trite is a major contributor to cytokine-induced myocardial contractile
failure. Circ Res. 2000;87:241-7.
24. Ghosh S, Standen NB, Galin˜anes M. Failure to precondition patho-
logical human myocardium. J Am Coll Cardiol. 2001;37:711-8.
Loubani and Galin˜anes Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 4 757
CS
P
